

UPDATE ON INTERNATIONAL NONPROPRIETARY NOMENCLATURE



The next Consultation of the International Nonproprietary Names (INN) Committee of the World Health Organization will be held November 16-18, 2010. All INN submissions to be discussed at this meeting must be received by the World Health Organization no later than **Monday, September 8th, 2010**.

The INN Committee has recently published proposed list #103.

Brand Institute and Drug Safety Institute are proud to have assisted on recent INN approvals!

avibactam	Novexel	fedovapagon	Vantia	simenepag	Allergan
bavisant	Johnson & Johnson	iniparib	Bipar	taprenepag	Pfizer
bedaquiline	Johnson & Johnson	lorvotuzumab mertansine	Immunogen	tasocitinib	Pfizer
cenicriviroc	Tobira	navitoclax	Abbott	tivantinib	Daiichi Sankyo
elpamotide	OncoTherapy Science	oxelumab	Genentech	verubulin	Myriad
ensituximab	NeoGenix Oncology	peginesatide	Affymax	vidofludimus	4SC
eteplirsen	AVI BioPharma	rezatomidine	Allergan	vorapaxar	Schering-Plough



Sophia V. Fuerst, M.S., M.B.A. *President of Nonproprietary Names Division, Drug Safety Institute*

Ms. Fuerst is the President of Drug Safety Institute's Nonproprietary (USAN/INN) Names Division. Since its founding in 2005, Sophia and her division have worked on over 130 USAN/INN Names. Prior to DSI, Ms. Fuerst served as the Director of the USAN Program at the American Medical Association (AMA) for five years and also served in several adjunct positions during her 18-year tenure with the Program.

In her position as Director of the USAN Program, Ms. Fuerst acted as chief liaison for negotiations between the USAN Council, pharmaceutical manufacturers and foreign nomenclature agencies. From 1986 to 2005, Ms. Fuerst was responsible for reviewing submissions, classifying compounds, creating new stems when appropriate and approving and adopting new USAN names.

Ms. Fuerst also sat on the World Health Organization (WHO/INN) Committee and served as AMA's senior staff scientist in the area of Drug Nomenclature. She has also received comprehensive training in the ATC classification system at the WHO Collaborating Centre for Drug Statistics Methodology.

Ms. Fuerst holds a B.S. in Biology/Chemistry (pre-med) from St. Joseph's College, an M.S. in Medicinal Chemistry from the University of Chicago and an M.B.A. from Governor's State University in Illinois.

Visit us at www.brandinstitute.com || www.drugsafetyinstitute.com

austin (512) 369-9100	chicago (312) 475-9600	frankfurt 49(0) 6196-400966	geneva 41(0) 22-819-1753	london 44(0) 207-240-2200	los angeles (310) 830-6111	miami (305) 374-2500
new york (212) 557-2100	ottawa (613) 761-1100	raleigh-durham (919) 572-9311	rockville (301) 984-1055	san francisco (415) 421-3200	tokyo 81(03) 6861-7517	toronto (416) 622-5777